Heart Test Laboratories (NASDAQ:HSCS) Given New $14.00 Price Target at Ascendiant Capital Markets

Heart Test Laboratories (NASDAQ:HSCS) had its price objective reduced by research analysts at Ascendiant Capital Markets from $15.00 to $14.00 in a research note issued on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Ascendiant Capital Markets’ price target suggests a potential upside of 362.05% from the company’s previous close.

Separately, Maxim Group restated a “buy” rating and set a $12.00 price objective on shares of Heart Test Laboratories in a report on Wednesday, December 18th.

Heart Test Laboratories Trading Down 3.8 %

Shares of NASDAQ:HSCS opened at $3.03 on Tuesday. Heart Test Laboratories has a 12-month low of $2.36 and a 12-month high of $13.50. The stock has a market cap of $2.97 million, a PE ratio of -0.38 and a beta of 2.77. The business has a 50 day moving average of $3.41 and a 200-day moving average of $3.43. The company has a quick ratio of 1.52, a current ratio of 1.72 and a debt-to-equity ratio of 0.01.

Heart Test Laboratories (NASDAQ:HSCS) last issued its quarterly earnings data on Thursday, March 13th. The company reported ($2.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.53) by ($0.04). As a group, equities research analysts forecast that Heart Test Laboratories will post -10.01 earnings per share for the current year.

About Heart Test Laboratories

Heart Test Laboratories, Inc, a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals.